TY - JOUR
T1 - Advancing precision psychiatry and targeted treatments
T2 - Insights from immunopsychiatry
AU - Miller, Andrew H.
AU - Berk, Michael
AU - Bloch, Gilles
AU - Briquet-Laugier, Veronique
AU - Brouillon, Carinne
AU - Cuthbert, Bruce N.
AU - Dantzer, Robert
AU - Davis, Michael C.
AU - De Picker, Livia J.
AU - Drevets, Wayne C.
AU - Eyre, Harris A.
AU - Hack, Laura M.
AU - Harrison, Neil A.
AU - Krystal, Andrew D.
AU - Lombardo, Giulia
AU - Mondelli, Valeria
AU - Pariante, Carmine M.
AU - Pulvirenti, Luigi
AU - Salvadore, Giacomo
AU - Sforzini, Luca
AU - Swieboda, Pawel
AU - Trivedi, Madhukar H.
AU - Leboyer, Marion
N1 - Publisher Copyright:
© 2025 Elsevier Inc.
PY - 2025/3
Y1 - 2025/3
N2 - Despite tremendous advancements in neuroscience, there has been limited impact on patient care. Current psychiatric treatments are largely non-specific, and drug development is hindered by outdated, overinclusive diagnostic categories and a “one-size-fits-all” approach. Additionally, mechanisms underlying psychiatric illnesses and their treatments with conventional medications remain poorly understood. Precision psychiatry is a strategy that holds great promise for novel therapies targeting specific pathophysiologic mechanisms in selected patients, ultimately contributing to more effective, personalized treatments. Immunopsychiatry, which focuses on the immune system's role in psychiatric disorders, exemplifies the challenges and potential solutions for precision psychiatry. Despite understanding how inflammation contributes to psychiatric illness, results of clinical trials with anti-inflammatory drugs have been inconsistent and underwhelming. Shortcomings of these trials include a lack of focus on subgroups of patients with increased inflammation, the use of non-specific outcome variables (e.g., not specific to inflammation's impact on the brain and behavior), and failure to establish target engagement of the inflammatory response. To advance anti-inflammatory treatments, clinical trials should: 1) enrich for patients using predictive biomarkers; 2) use clinical outcome assessments that align with inflammation's effects on the brain; 3) consider novel diagnostic constructs linked to inflammation; and 4) verify target engagement. Moreover, greater attention should be paid to efforts to repurpose available anti-inflammatory drugs while awaiting development of novel treatments targeting more specific immune pathways. Taken together, a collaborative approach involving academia, industry, funding agencies, patients, payors, and policymakers is required to advance Immunopsychiatry and ultimately provide a roadmap for successful implementation of precision psychiatry.
AB - Despite tremendous advancements in neuroscience, there has been limited impact on patient care. Current psychiatric treatments are largely non-specific, and drug development is hindered by outdated, overinclusive diagnostic categories and a “one-size-fits-all” approach. Additionally, mechanisms underlying psychiatric illnesses and their treatments with conventional medications remain poorly understood. Precision psychiatry is a strategy that holds great promise for novel therapies targeting specific pathophysiologic mechanisms in selected patients, ultimately contributing to more effective, personalized treatments. Immunopsychiatry, which focuses on the immune system's role in psychiatric disorders, exemplifies the challenges and potential solutions for precision psychiatry. Despite understanding how inflammation contributes to psychiatric illness, results of clinical trials with anti-inflammatory drugs have been inconsistent and underwhelming. Shortcomings of these trials include a lack of focus on subgroups of patients with increased inflammation, the use of non-specific outcome variables (e.g., not specific to inflammation's impact on the brain and behavior), and failure to establish target engagement of the inflammatory response. To advance anti-inflammatory treatments, clinical trials should: 1) enrich for patients using predictive biomarkers; 2) use clinical outcome assessments that align with inflammation's effects on the brain; 3) consider novel diagnostic constructs linked to inflammation; and 4) verify target engagement. Moreover, greater attention should be paid to efforts to repurpose available anti-inflammatory drugs while awaiting development of novel treatments targeting more specific immune pathways. Taken together, a collaborative approach involving academia, industry, funding agencies, patients, payors, and policymakers is required to advance Immunopsychiatry and ultimately provide a roadmap for successful implementation of precision psychiatry.
KW - Anti-inflammatory drugs
KW - Biomarkers
KW - Clinical Outcome Assessments
KW - Clinical Trials
KW - Depression
KW - Drug development
KW - Immunopsychiatry
KW - Inflammation
KW - Personalized Medicine
KW - Psychiatry
UR - http://www.scopus.com/inward/record.url?scp=85215366240&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85215366240&partnerID=8YFLogxK
U2 - 10.1016/j.bbi.2025.01.002
DO - 10.1016/j.bbi.2025.01.002
M3 - Review article
C2 - 39828008
AN - SCOPUS:85215366240
SN - 0889-1591
VL - 125
SP - 319
EP - 329
JO - Brain, behavior, and immunity
JF - Brain, behavior, and immunity
ER -